Amanote Research
Register
Sign In
Pcn311 - European Market Access Challenges for Relapsed Refractory Multiple Myeloma Triplet Therapies
Value in Health
- United Kingdom
doi 10.1016/j.jval.2018.09.393
Full Text
Open PDF
Abstract
Available in
full text
Categories
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Date
October 1, 2018
Authors
I. Stefani
A. Brough
E. McKee
E. Lyons
Publisher
Elsevier BV
Related search
Carfilzomib for Relapsed or Refractory Multiple Myeloma
The Lancet Oncology
Oncology
Psy63 - Cost by Outcomes Analysis of Novel Triple-Combination Therapies for Relapsed/Refractory Multiple Myeloma in Brazil
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Pcn173 - Cost-Effectiveness of New Triplet Combinations With Lenalidomide and Dexamethasone for Patients With Relapsed or Refractory Multiple Myeloma
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Bendamustine in Patients With Relapsed or Refractory Multiple Myeloma
European Journal of Medical Research
Medicine
Bendamustine, Pomalidomide, and Dexamethasone for Relapsed and/or Refractory Multiple Myeloma
Blood Cancer Journal
Oncology
Hematology
Phase 1b Trial of Pembrolizumab Monotherapy for Relapsed/Refractory Multiple Myeloma: KEYNOTE ‐013
British Journal of Haematology
Hematology
Multitargeted Therapies for Multiple Myeloma
Autophagy
Cell Biology
Molecular Biology
Multicenter, Phase I, Dose-Escalation Trial of Lenalidomide Plus Bortezomib for Relapsed and Relapsed/Refractory Multiple Myeloma
Journal of Clinical Oncology
Cancer Research
Medicine
Oncology
Letter: Quest for the Best in Relapsed/Refractory Multiple Myeloma: A Mis-Placed ENDEAVOR
Clinical Therapeutics
Pharmacology
